Legal Opinion
Astrazeneca AB v. Mylan Pharmaceuticals, Inc.
District Court, D. Delaware
Decided November 5, 2014No. Civil Action No. 14-696-GMSPublishedCited by 28 opinions
1Opinion of the Court
OPINION
SLEET, U.S. District Judge
I. INTRODUCTION
AstraZeneca AB (“AstraZeneca”) filed a complaint against defendant Mylan Pharmaceuticals, Inc. (“Mylan”) on June 2, 2014, alleging patent infringement of U.S. Patent Nos. 7,951,400 (“the '400 Patent”), RE44,186 (“the Í186 Patent”), and 8,628,-799 (“the '799 Patent”). (D.I. 1.) The cause of action was triggered when Mylan filed two Abbreviated New Drug Applications (“ANDA”) Nos. 205980 and 205981 with the U.S, Food and Drug Administration (“FDA”) for approval to market saxa-glitptin hydrochloride tablets — generic versions of AstraZeneca’s…
2Cases cited31 opinions
- International Shoe Co. v. WashingtonSupreme Court of the United States · 1945
- Burger King Corp. v. RudzewiczSupreme Court of the United States · 1985
- World-Wide Volkswagen Corp. v. WoodsonSupreme Court of the United States · 1980
- Helicopteros Nacionales De Colombia, S. A. v. HallSupreme Court of the United States · 1984
- Daimler AG v. BaumanSupreme Court of the United States · 2014
26 more not listed; retrieve them via the Exa API.
3Cited by28 opinions
- Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.Court of Appeals for the Federal Circuit · 2016
- Otsuka Pharmaceutical Co. v. Mylan Inc.District Court, D. New Jersey · 2015
- Senju Pharmaceutical Co. v. Metrics, Inc.District Court, D. New Jersey · 2015
- Gorton v. Air & Liquid Sys. Corp.District Court, M.D. Pennsylvania · 2018
- Acorda Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.District Court, D. Delaware · 2015
23 more not listed; retrieve them via the Exa API.